Ionis Pharmaceuticals, Inc. (IONS)

Brightcove Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Research and Development	407.74M	412.20M	517.20M	519.24M	476.54M	479.40M	305.40M	332.63M
Research and Development Growth	-14.44%	-14.02%	69.35%	56.10%	71.59%	68.45%	-46.00%	-36.82%
Commercial	309.94M	293.36M	286.36M	294.71M	300.57M	308.75M	309.75M	298.08M
Commercial Growth	3.12%	-4.98%	-7.55%	-1.13%	0.74%	1.94%	-0.04%	-7.51%

Revenue by Product

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Spinraza	225.96M	216.41M	214.41M	224.45M	228.72M	240.51M	245.51M	239.91M
Spinraza Growth	-1.21%	-10.02%	-12.67%	-6.44%	-4.11%	-0.65%	0.58%	-3.66%
Tegsedi and Waylivra	30.83M	33.74M	34.74M	34.11M	36.57M	34.42M	32.42M	30.05M
Tegsedi and Waylivra Growth	-15.69%	-1.96%	7.17%	13.49%	22.78%	16.81%	3.03%	-26.82%
Wainua	28.52M	20.28M	10.28M	4.91M	1.13M	-	-	-
Wainua Growth	2,435.47%	-	-	-	-	-	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.